IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control OngoingThis phase 3 trial tests ravulizumab, a drug that blocks part of the immune system, against a placebo in 579 adults with IgA nephropathy—a kidney disease that can lead to kidney failure. The goal is to see if ravulizumab reduces protein in the urine and preserves kidney function …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to slow kidney failure in common kidney disease
Disease control OngoingThis phase 3 trial tests whether the drug atrasentan can slow kidney function loss in people with IgA nephropathy, a disease that can lead to kidney failure. About 404 participants receive either atrasentan or a placebo, along with standard care. The main goal is to see if atrase…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug aims to plug kidney leaks in multiple diseases
Disease control OngoingThis phase 2 study tests the drug atrasentan in 103 adults with various kidney diseases that cause protein leakage, including IgA nephropathy and FSGS. Participants take a daily tablet to see if it reduces protein in urine, a sign of kidney damage. The goal is to find a new way t…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control OngoingThis phase 3 trial tests whether the drug povetacicept can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a kidney disease. About 605 participants will receive either the drug or a placebo by injection. The study is active but not recruit…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug shows promise for slowing kidney disease in IgA nephropathy patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called sibeprenlimab for people with IgA nephropathy, a kidney disease. About 600 adults who completed earlier trials of this drug will continue receiving it for up to 2 more years. Researchers will track side effects and measure…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2, PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control OngoingThis Phase 3 trial tests sparsentan, a new drug, against irbesartan (a standard treatment) in 406 adults with IgA nephropathy, a kidney disease. The goal is to see if sparsentan better protects kidney function over about 2 years. Participants must have significant protein in thei…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New shot shows promise in slowing kidney disease
Disease control OngoingThis phase 3 study tests BION-1301 (Zigakibart) in 383 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants receive either the drug or a placebo as a shot every 2 weeks for 2 years. The main goal is to see if the drug helps preserve kidney f…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug shows promise for tough kidney diseases
Disease control OngoingThis study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 mo…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC